a dog that will hunt. If you’ve seen any of the poster presentations you’d know this is going to be a decent drug to sell. Certainly launched better than Rytary and Lyvispah. It’s not going to be a blockbuster but it will be pretty decent.
The way you all launched BOTH products it would not be difficult to launch a dirty diaper better LOL How many Lyvispah writers do you have? Hell, the volume most have of Rytary is also pretty pathetic.
Have YOU seen the poster presentations? The results are lackluster.
IPX is only a bit better than Rytary:
- average dosing in both studies for IR was 5. For Rytary it was 3.6 and for IPX it’s about 3. Yea it’s better not not by much. It certainly won’t have very many patients cut a dosing interveral.
- compared to IR Rytary gave 1.2 hours more on time per dose and IPX 1.55 hours. That’s a change for certain but not much of one.
The disappointing results of IPX coupled with the convoluted dosing, and Rytary going generic, isn’t really promising. Add a dash of Amneal being totally run by a bunch of bozos and the outlook isn’t good.
Over half the salesforce has little to no volume of Rytary. Even still, they are hoping to convert people as the “lowest hanging fruit.” If you talk with HCPs you’ll find that it won’t be as easy as they make it out to be. There is little sense in converting a patient to an expensive poorly covered drug when the benefit won’t even be a dosing interval cut off.
Rytary is better than IR and it’s a tough sell to most HCPs, even after all these years. It’s naive to think this isn’t going to be a very very tough battle ahead.
I am hopeful for you all that it will still be launched, and everyone will keep their job. However, it’s really naive to have the stance of “Dog will hunt.”